


CLAIMS

1. 2-(3,5-dichloro-1-methyl-indazol-4-yl)-1-[(1S,3R)-3-(hydroxymethyl)-5-(1-hydroxy-1-methyl-ethyl)-1-methyl-3,4-dihydro-1H-isoquinolin-2-yl]ethanone of formula (I), or a
 5 pharmaceutically acceptable salt thereof,



(I)

2. A compound of formula (I) according to claim 1, or a pharmaceutically acceptable salt thereof, for use in therapy.
3. A compound of formula (I) as defined in Claim 1, or a pharmaceutically acceptable salt thereof, for use in the treatment and/or prevention of diseases and/or disorders in which
 10 D1 receptors play a role.
4. A compound of formula (I) as defined in Claim 1, or a pharmaceutically acceptable salt thereof, for use in the treatment and/or prevention of cognitive and negative symptoms in schizophrenia, cognitive impairment related to neuroleptic therapy, Mild Cognitive
 15 impairment (MCI), impulsivity, Attention-Deficit Hyperactivity Disorder (ADHD), Parkinson's disease and other movement disorders, dystonia, Parkinson's dementia, Huntington's disease, dementia with Lewy Body, Alzheimer's disease drug addiction, sleep disorders, apathy, traumatic spinal cord injury or neuropathic pain.
5. A compound of formula (I) as defined in Claim 1, or a pharmaceutically acceptable salt thereof, for use in the treatment of Parkinson's disease and other movement disorders,
 20 Alzheimer's disease, or cognitive and negative symptoms in schizophrenia.
6. A pharmaceutical composition comprising a compound of formula (I) as defined in Claim 1, or a pharmaceutically acceptable salt thereof, in association with a pharmaceutically acceptable carrier.
7. A method for the treatment and/or prevention of disorders for which the administration
 25 of D1 positive allosteric modulator is indicated, which comprises administering to a patient in need of such treatment an effective amount of a compound of formula (I) as defined in Claim 1, or a pharmaceutically acceptable salt thereof.
8. A method for the treatment and/or prevention of cognitive and negative symptoms in
 30 schizophrenia, cognitive impairment related to neuroleptic therapy, Mild Cognitive

- 5 impairment (MCI), impulsivity, Attention-Deficit Hyperactivity Disorder (ADHD),
Parkinson's disease and other movement disorders, dystonia, Parkinson's dementia,
Huntington's disease, dementia with Lewy Body, Alzheimer's disease drug addiction,
sleep disorders, apathy, traumatic spinal cord injury or neuropathic pain, which
comprises administering to a patient in need of such treatment an effective amount
of a compound of formula (I) as defined in Claim 1, or a pharmaceutically acceptable
salt thereof.
- 10 9. A method for the treatment of Parkinson's disease and other movement disorders,
Alzheimer's disease, or cognitive and negative symptoms in schizophrenia which
comprises administering to a patient in need of such treatment of an effective amount
of a compound of formula (I) as defined in Claim 1, or a pharmaceutically acceptable
salt thereof.